

## Cannabinoid-Based Therapies, CBIS Forges Ahead with Cannabis-Based Cancer Treatments


Cannabis Science (OTC: CBIS), GW Pharmaceuticals plc (NASDAQ: GWPH), ENDEXX Corp. (OTC: EDXC), Medbox, Inc. (OTC: MDBX) and Medical Marijuana, Inc. (OTC: MJNA)

BOCA RATON, FL, USA, June 2, 2014 /EINPresswire.com/ -- Development of Cannabinoid-Based Therapies Becoming More Prevalent By Leaps and Bounds CBIS Forges Ahead with Cannabis-Based Cancer Treatments

<u>Cannabis Science</u> (OTC: CBIS) Takes Revolutionary Steps Toward Cannabis-Based Cancer Treatments

Perhaps the only thing evolving faster than the global economy are the political and cultural trends of 21st Century American society, and one trend that has marked the last decade is a widespread shift toward the embracement of the healing and medicinal effects of cannabinoid-based therapies.

Enter Cannabis Science, Inc. (OTC: CBIS), a biotech-that-could which has adopted a novel approach toward converting cultural cannabis trends into meaningful, long-lasting treatments for some of the most serious ailments affecting the human race, including cancer, AIDS, arthritis, and others. Cannabis Science employs a business model characterized by an openness to



partnership, as well as research and development fueled by thorough clinical trials and lead by a team of top biochemistry and pharmaceutical scientists. Biotech-hunting investors need look no further to snatch up a worthwhile piece of the vibrant cannabinoid market \_ currently valued at up to \$50 billion and rising as CBIS is currently trading at .092 per share with a volume of over 7M.

As one of the first publicly-traded cannabinoid companies on the market, Cannabis Science takes the development of medicinal cannabinoid therapies to new frontiers in multiple ways, one of which is its promising INDs (Investigational New Drugs). Based on research published earlier this year, the Company has formulated CS-TATI-1, a cannabinoid extract that is thought to combat Epidemic Kaposi Sarcoma, a form of cancer brought on by certain strains of the HIV virus. Cannabis Science is also developing CS-S/BCC-1, a topically-applied cannabinoid extract that has been used to successfully treat skin cancer patients. The company expects to convert CS-S/BCC-1 into both over-the-counter and prescription treatments, with the first steps toward FDA-approval underway/

In addition to the development of their own in-house cannabinoid-based therapies, Cannabis Sciences has cultivated an active partnership with New Colombia Resources and the Phoenix Tears Foundation, with plans to oversee clinical trials in Colombia for a cancer-treating oil formulated by Phoenix Tears Foundation. The promising results of the drug have encouraged both sides to pursue an IND application with the FDA.

<u>Dr. Robert Melamede</u>, who is the scientific advisor to New Colombia Resources, serves as the link between the two companies: he also acts as the President of Cannabis Sciences. A biochemistry expert and biology professor at the University of Colorado, Dr. Melamede is a leading authority on cannabinoid therapies and even has experience working for businesses in the field of cancer research. His unique expertise are an ideal fit for the long term research and company goals of Cannabis Science.

The Company has also partnered with Dutch outfit Mediwiet, the largest European organization of patients obtaining medical treatment with cannabis. Mediwiet patients only consume orally-administered cannabis, and the majority of the company's constituents have never used the drug recreationally. Cannabis Science will partner with Mediwiet to conduct one of the largest joint Clinical Observational Studies on this subject in the world. It aims to gather observational data on a large portion of Mediwiet patients using cannabis-based medicines for the treatment of ailments ranging from epilepsy to Alzheimer's to chronic pain.

These partnerships represent only a handful of the new ventures conducted by Cannabis Science to further the research, development, and economy of cannabinoid medicinal treatments. The Company's commitment to this burgeoning industry is multifaceted: through shareholder loyalty, the creation of revolutionary new products, and a financially and scientifically nuanced leadership that recognizes the importance of attaining its goals, Cannabis Science embodies all the makings of a future biotech leader.

For more info on CBIS and other small cap companies, join our email newsletter <a href="https://www.ragingbullalerts.com">www.ragingbullalerts.com</a>

About Cannabis Science, Inc.

http://www.cannabisscience.com/

https://www.facebook.com/cbisinc

https://twitter.com/cannabisscienc1

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands ars, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works

with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Full disclaimer in regards to this article <a href="http://tomorrowsbluechips.com/disclaimer/">http://tomorrowsbluechips.com/disclaimer/</a>

## Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," "intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs.

Lou Levenstein Seraphim Strategies 5613741482 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2015 IPD Group, Inc. All Right Reserved.